Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Annals of the New York Academy of Sciences
|
February 24, 2001
Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42
D Games, F Bard, H Grajeda, et al.
Neuroscience Letters
|
October 21, 1998
Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC)
R J Ellis, P Seubert, R Motter, et al.
The Journal of Biological Chemistry
|
June 5, 1990
The protease inhibitory properties of the Alzheimer's beta-amyloid precursor protein
S Sinha, H F Dovey, P Seubert, et al.
Vaccine
|
July 18, 2001
Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice
D J Brayden, L Templeton, S McClean, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 18, 1997
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease
K Johnson-Wood, M Lee, R Motter, et al.
Archives of Neurology
|
July 25, 1998
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
D Galasko, L Chang, R Motter, et al.
Neurobiology of Disease
|
January 1, 1997
Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue
M B Podlisny, M Citron, P Amarante, et al.
Annals of Neurology
|
June 1, 1997
A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes
T Gómez-Isla, W Wasco, W P Pettingell, et al.
Neurobiology of Aging
|
January 4, 2011
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease
L M Bekris, N M Galloway, S Millard, et al.
Nature Medicine
|
August 10, 2000
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard, C Cannon, R Barbour, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Annals of the New York Academy of Sciences
|
February 24, 2001
Prevention and reduction of AD-type pathology in PDAPP mice immunized with A beta 1-42
D Games, F Bard, H Grajeda, et al.
Neuroscience Letters
|
October 21, 1998
Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans. HIV Neurobehavioral Research Center Group (HNRC)
R J Ellis, P Seubert, R Motter, et al.
The Journal of Biological Chemistry
|
June 5, 1990
The protease inhibitory properties of the Alzheimer's beta-amyloid precursor protein
S Sinha, H F Dovey, P Seubert, et al.
Vaccine
|
July 18, 2001
Encapsulation in biodegradable microparticles enhances serum antibody response to parenterally-delivered beta-amyloid in mice
D J Brayden, L Templeton, S McClean, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 18, 1997
Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease
K Johnson-Wood, M Lee, R Motter, et al.
Archives of Neurology
|
July 25, 1998
High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype
D Galasko, L Chang, R Motter, et al.
Neurobiology of Disease
|
January 1, 1997
Presenilin proteins undergo heterogeneous endoproteolysis between Thr291 and Ala299 and occur as stable N- and C-terminal fragments in normal and Alzheimer brain tissue
M B Podlisny, M Citron, P Amarante, et al.
Annals of Neurology
|
June 1, 1997
A novel presenilin-1 mutation: increased beta-amyloid and neurofibrillary changes
T Gómez-Isla, W Wasco, W P Pettingell, et al.
Neurobiology of Aging
|
January 4, 2011
Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease
L M Bekris, N M Galloway, S Millard, et al.
Nature Medicine
|
August 10, 2000
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
F Bard, C Cannon, R Barbour, et al.
Page
of 6